Close Menu
    What's Hot

    UK Bulk Annuity Insurers’ Exposure to Private Credit Set To Remain Manageable

    July 20, 2026

    UK Bulk Annuity Insurers’ Exposure to Private Credit Set To Remain Manageable

    July 20, 2026
    Milliman

    Competitive US Pension Risk Transfer Cost Decreased During June

    July 20, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Big Year of Growth for Life/Annuity Sidecar-Like Activity in 2025

      July 2, 2026

      Sixth Street To Become Majority Shareholder of Monument Re

      June 30, 2026

      Pacific Life Re Appoints Florence Durousseau as Head of Capital Solutions, Europe

      June 15, 2026

      Third Block Reinsurance Deal With Tokio Marine & Nichido Life for Pacific Life Re

      June 10, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Q&A: Dr Christoph Schmitt, Director, Insurance, Fitch Ratings

      May 28, 2026

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Annuity Sales Notch Tenth Consecutive $100bn+ Quarter

      May 11, 2026

      UK Bulk Annuity Insurers’ Exposure to Private Credit Set To Remain Manageable

      July 20, 2026

      UK Bulk Annuity Insurers’ Exposure to Private Credit Set To Remain Manageable

      July 20, 2026
      Milliman

      Competitive US Pension Risk Transfer Cost Decreased During June

      July 20, 2026

      Rolls-Royce Completes Bulk Purchase Annuity Buy-Out Transition With PIC

      July 16, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026

      Optimism for Stronger Second Half in the Life Settlement Tertiary Market

      July 8, 2026

      US Life Insurers Embrace Securitised Credit as Demand for Yield and Diversification Grows but Hurdles Remain for Longevity-Linked Assets

      July 8, 2026

      UK Equity Release Market Waits on Fourth Quarter for Potentially Market-Altering Change

      June 24, 2026

      Q&A: James Westerlind, Partner, ArentFox Schiff

      June 24, 2026

      UK Bulk Annuity Insurers’ Exposure to Private Credit Set To Remain Manageable

      July 20, 2026

      UK Bulk Annuity Insurers’ Exposure to Private Credit Set To Remain Manageable

      July 20, 2026
      Milliman

      Competitive US Pension Risk Transfer Cost Decreased During June

      July 20, 2026

      Rolls-Royce Completes Bulk Purchase Annuity Buy-Out Transition With PIC

      July 16, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026

      Editor’s Letter – Volume 2, Issue 6, June 2026

      June 10, 2026

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026

      Editor’s Letter – Volume 2, Issue 3, March 2026

      March 11, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    Q&A: Swapnil Katkar, Partner, EY

    Longevity and Mortality Risk Transfer October 9, 2024By Greg Winterton
    Share
    Twitter LinkedIn Email

    EY recently appointed Swapnil Katkar as a new Partner in the firm’s London office where he will lead the bulk purchase annuity (BPA) and capital markets solutions business at the firm. Greg Winterton caught up with Katkar to get his take on the current state of the BPA market and his views on the outlook for the coming 12-18 months. 

    GW: Swapnil, the growth in the UK BPA market is not only made manifest in the number of deals being completed, but also evidenced by the recent and planned entries of new insurers into the market. What is your view of the reality of just how large this market can grow to on an annual basis?  

    SK: The BPA market experienced substantial growth during 2023. This was largely driven by higher interest rates and credit spreads making BPA transactions a lot more affordable compared to 2022, and attractive in terms of value for money that these transactions offered to pension schemes. We estimate that around 225-250 BPA transactions were executed across nine BPA providers in 2023, covering a total deal volume of c.£45-50bn (compared to c.£25-30bn in 2022). 

    The growth in the BPA market during 2023 attracted new entrants, and we expect around 11 BPA providers to be ready to conduct business by H1 2025. New entrants will likely focus on smaller deals initially, giving pension schemes under £200m in size additional options and potentially better pricing.  

    Despite this, we are seeing more subdued growth in the BPA market in 2024 so far and anticipate lower annual growth in total deal volume this year. This is largely a result of weaker affordability due to tighter pricing (driven by low credit spreads) and due to fewer deals over £1bn in size – which were key in driving deal volume in 2023. 

    GW: Let’s talk interest rates. The Bank of England reduced rates recently, and there are doves on the Monetary Policy Committee that want further cuts. What is the hedging status of most of the plans you work with? Are they sufficiently protected from further cuts? Indeed, are the days of schemes’ funding status whipsawing gone now?  

    SK: Interest rates are forecast to continue to fall over the coming years, although the level and timing of future rate cuts remains to be seen. However, for pension scheme hedging, the most important aspect is long dated interest rates.  

    Looking back, a ten-year gilt yield – which could be seen as proxy interest rate for hedging purposes – has jumped from less than 1% pa to around 4% since 2022, substantially improving the pension scheme funding levels. 

    Many pension schemes have hedged their interest rate and inflation exposure embedded in pension liabilities on the scheme’s funding basis. However, the majority of pension schemes likely remain under-hedged on a buyout basis, representing a higher liability compared to an average funding basis.  

    Overall, we anticipate that the days of schemes’ funding status “whipsawing” – when pension liabilities go up and down materially more than pension scheme assets due to interest rate fluctuations – are largely gone, as the vast majority of schemes have largely hedged this exposure. However, that’s not to say that other factors won’t contribute to future fluctuations in funding levels. 

    GW: What’s your view on concentration risk? There is an awful lot of pension liabilities hitting the balance sheets of life insurers and consequently, reinsurers.  

    SK: Concentration risk is currently an issue for the life insurance industry and its regulator, the Prudential Regulation Authority (PRA). It is mainly driven by funded reinsurance transactions whereby, for instance, a UK BPA insurer reinsures a proportion of its pension liabilities with an offshore reinsurer. Given its limited oversight and control over offshore reinsurers, the PRA has been looking at this area closely and has recently published the final policy statement on the use of funded reinsurance. This statement focuses on the need for BPA providers to consider diversification between funded reinsurance counterparties, and how they will set internal limits for any recapture of collateral from a single reinsurance counterparty. 

    This is likely to create significant operational change for BPA insurers as they put new processes in place to demonstrate compliance and how they are mitigating the concentration risk.  

    From a pension scheme standpoint, typically, an entire pension scheme liability is insured with a single BPA insurer under the BPA contract. This is the concentration risk the pension scheme is directly exposed to, in addition to indirect exposure to sources like concentration risk within the BPA insurer’s investment strategy or its funded reinsurance strategy. This means pension schemes need to carefully consider all aspects of concentration risk when looking into executing a BPA transaction and the potential measures to mitigate this risk. 

    GW: What’s on your radar in terms of longevity/mortality trends? What are insurance companies and pension fund trustees currently discussing here that is impacting pricing, if at all?  

    SK: From a risk standpoint, post the Covid-19 pandemic, we are seeing less excitement among pension schemes to hedge longevity risk. In fact, the growth in the BPA market means that several schemes with legacy longevity hedges in place continue to assess opportunities to convert these into funded BPA contracts, especially as a number of these legacy longevity hedges are running at a loss. 

    We also see that the mortality assumptions used by pension schemes are now more aligned with the assumptions used by BPA providers, creating less impact in terms of any deficit on BPA basis.  

    Separately, there are continued developments in the reinsurance market which means the reinsurers now have substantial ability and appetite to provide longevity protection against longer duration liabilities (i.e.: on younger lives). This means pension schemes now have more choice in terms of hedging longevity attractively, either via BPA transaction or a longevity swap directly in the reinsurance market. 

    GW: Lastly, Swapnil, if you’re a pension trustee reading this who has not yet begun the journey towards an insurance solution, what’s your recommendation in terms of where to start?  

    SK: A pension trustee looking for an insurance solution could start by reviewing their strategic objectives as a key part of their journey planning. This could either be done upfront before executing any strategy or on a regular basis, for example, when the trustee board meets quarterly. Given the financial environment tends to change at pace, a more regular review would be recommended to ensure previously agreed objectives remain relevant and suitable.  

    In addition, given the range of strategic options available to pension trustees today – from run-on to buyout, from captive insurance to DB superfunds, from longevity hedging to self-insurance – it is recommended that these options are carefully considered before deciding on a chosen strategy. This could make a substantial difference to the long-term outcome for scheme members in terms of benefits received and the security of those benefits. This will also ensure that the pension trustees and corporate sponsors are reasonably aligned on the chosen strategy. 

    Swapnil Katkar is a Partner at EY in London  

    2024 - October Longevity Risk Pension Risk Transfer Q&A Volume 3 Issue 10 - October 2024
    Share. Twitter LinkedIn Email

    Related Posts

    UK Bulk Annuity Insurers’ Exposure to Private Credit Set To Remain Manageable

    July 20, 2026By LMI Newsdesk

    UK Bulk Annuity Insurers’ Exposure to Private Credit Set To Remain Manageable

    July 20, 2026By LMI Newsdesk
    Milliman

    Competitive US Pension Risk Transfer Cost Decreased During June

    July 20, 2026By LMI Newsdesk

    Rolls-Royce Completes Bulk Purchase Annuity Buy-Out Transition With PIC

    July 16, 2026By LMI Newsdesk
    Latest Issue

    Optimism for Stronger Second Half in the Life Settlement Tertiary Market

    July 8, 2026

    Organ Transplant Improvements Test Life Expectancy Assessment Models

    July 8, 2026

    US Life Insurers Embrace Securitised Credit as Demand for Yield and Diversification Grows but Hurdles Remain for Longevity-Linked Assets

    July 8, 2026

    Passage of UK Pension Schemes Act Seen Boosting Size of DB Superfund Market

    June 24, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.